Pharmafile Logo

Cometriq

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

- PMLiVE

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy

- PMLiVE

UK government allocates up to £680m a year to two funds offering cutting-edge treatments

The new Innovative Medicines Fund will enable patients in England to gain fast-track access to drug treatments

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

Roche’s Tecentriq/Avastin combo improves survival in liver cancer

First regimen to achieve improved overall survival in ten years

- PMLiVE

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Another important milestone for Roche's Tecentriq plans

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links